WHO recommendations for the viruses used in the 2013–2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013

2014/02/28 by Ian Barr, Ian G. Barr, Colin Russell +25 · 26 citations
Medicine · Agricultural and Biological Sciences · #Influenza Virus Research Studies #Respiratory viral infections research #Animal Disease Management and Epidemiology

paper · doi:10.1016/j.vaccine.2014.02.014

Abstract

In February the World Health Organisation (WHO) recommends influenza viruses to be included in influenza vaccines for the forthcoming winter in the Northern Hemisphere. These recommendations are based on data collected by National Influenza Centres (NICs) through the WHO Global Influenza Surveillance and Response System (GISRS) and a more detailed analysis of representative and potential antigenically variant influenza viruses from the WHO Collaborating Centres for Influenza (WHO CCs) and Essential Regulatory Laboratories (ERLs). This article provides a detailed summary of the antigenic and genetic properties of viruses and additional background data used by WHO experts during development of the recommendations of the 2013-2014 Northern Hemisphere influenza vaccine composition.

Cited by

• Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses
• Computational prediction of vaccine strains for human influenza A (H3N2) viruses. [europepmc]
• Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. [europepmc]
• Focused antibody response to influenza linked to antigenic drift. [europepmc]
• Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015). [europepmc]
• Deep Sequencing Reveals Potential Antigenic Variants at Low Frequencies in Influenza A Virus-Infected Humans. [europepmc]
• Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses. [europepmc]
• Identification of Low- and High-Impact Hemagglutinin Amino Acid Substitutions That Drive Antigenic Drift of Influenza A(H1N1) Viruses. [europepmc]
• The Molecular Determinants of Antibody Recognition and Antigenic Drift in the H3 Hemagglutinin of Swine Influenza A Virus. [europepmc]
• Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017. [europepmc]
• Development of an Alternative Modified Live Influenza B Virus Vaccine. [europepmc]
• Predictive Modeling of Influenza Shows the Promise of Applied Evolutionary Biology. [europepmc]
• Genome-wide evolutionary dynamics of influenza B viruses on a global scale. [europepmc]
• The WHO global influenza surveillance and response system (GISRS)-A future perspective. [europepmc]
• Influenza. [europepmc]
• Plasticity of Amino Acid Residue 145 Near the Receptor Binding Site of H3 Swine Influenza A Viruses and Its Impact on Receptor Binding and Antibody Recognition. [europepmc]
• Seasonal Genetic Drift of Human Influenza A Virus Quasispecies Revealed by Deep Sequencing. [europepmc]
• Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018. [europepmc]
• Comparison of antigenic mutation during egg and cell passage cultivation of H3N2 influenza virus. [europepmc]
• Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-derived Quadrivalent Influenza Vaccines in Preventing Influenza-like Illness in 2017-2018. [europepmc]
• Predicting the short-term success of human influenza virus variants with machine learning. [europepmc]
• Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization Assays. [europepmc]
• Enhanced isolation of influenza viruses in qualified cells improves the probability of well-matched vaccines. [europepmc]
• Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron. [europepmc]
• Can primary care physician recommendation improve influenza vaccine uptake among older adults? A community health centre-based experimental study in China. [europepmc]
• Co-Administration of Influenza and COVID-19 Vaccines: Policy Review and Vaccination Coverage Trends in the European Union, UK, US, and Canada between 2019 and 2023. [europepmc]

Related

• H7N9: Preparing for the Unexpected in Influenza
• Influenza viruses – antiviral therapy and resistance
• Inno4Vac Workshop Report Part 1: Controlled Human Influenza Virus Infection Model (CHIVIM) Strain Selection and Immune Assays for CHIVIM Studies, November 2021, MHRA, UK
• Antibodies elicited by the 2025-2026 influenza vaccine in humans
• JMM Profile: Swine influenza A virus: a neglected virus with pandemic potential